Form 4: Pfizer CEO Albert Bourla Reports Acquisition of Phantom Stock Units

Pfizer's Chairman and CEO, Albert Bourla, reports the acquisition of 1,484 phantom stock units through the company's deferred compensation plan.

Summary

• On April 10, 2025, Albert Bourla, the Chairman & CEO of Pfizer Inc., acquired 1,484 phantom stock units.
• These units were obtained through the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan.
• Each unit represents one phantom share of Pfizer common stock.
• The acquisition price is $21.59 per unit.
• Following the transaction, Bourla directly owns 707,507 shares.
• The phantom stock units are settled in cash after Bourla's separation from service and can be transferred into an alternative investment account at any time.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction related to executive compensation, suggesting a neutral to slightly positive sentiment as it indicates continued investment in the company by its CEO.

Positives

• The acquisition of phantom stock units aligns the CEO's interests with the long-term performance of the company.
• The deferred compensation plan allows for tax-advantaged savings.

Future Outlook

The document does not contain any specific forward-looking statements or guidance.

Industry Context

This filing is a routine disclosure related to executive compensation and is common for publicly traded companies. It reflects standard practices for aligning executive incentives with shareholder value.

Comparison to Industry Standards

• Deferred compensation plans, including phantom stock units, are a common component of executive compensation packages in large publicly traded companies like Pfizer.
• Companies such as Johnson & Johnson, Merck, and AbbVie also utilize similar deferred compensation strategies to attract and retain top talent.
• The specific terms and amounts of these plans vary based on company size, performance, and individual executive agreements.

Stakeholder Impact

• The transaction has a minor positive impact on shareholders as it aligns executive compensation with company performance.
• Employees may view the deferred compensation plan as a positive benefit for executives.

Key Dates

Keywords

Pfizer, Albert Bourla, phantom stock units, deferred compensation, Form 4, SEC, PFE, beneficial ownership